$BLLN

Sakakibara Shan Riku sold $1.0M of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at $125.00 ($1.00M total) across 5 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jul 13, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest disclosed fact is the CPO’s $1.0M open-market sale under a pre-arranged 10b5-1 plan; it does not include any new business, clinical, or regulatory development.

02

Market read

Traders may treat this as low-signal insider activity rather than a fundamental catalyst, but it can marginally influence short-term sentiment.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same time, nor does it provide context on option exercises, tax-related liquidity needs, or planned future tranches.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-13, transaction dated 2026-07-09

Background

This is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

BillionToOne insider Form 4 shows CPO Sakakibara Shan Riku sold 8,000 shares at $125 on a 10b5-1 plan, totaling $1.0M.

Expected impact

Low likelihood of a sustained price move solely from this transaction; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 details a pre-arranged 10b5-1 plan and a single-day sale at a fixed price, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as this is company-specific insider trading with no disclosed operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can coincide with internal expectations of limited upside, so traders may still watch for follow-on selling or weak demand signals.

Key entities

  • BillionToOne, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Sakakibara Shan Riku

    Chief Product Officer who sold shares under a 10b5-1 plan.

Related articles

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.